Baxter has announced distribution agreement with bioMérieux, for the NEPHROCLEAR CCL14 diagnostic test, currently in development for use in assessing the risk of developing persistent severe acute kidney injury (AKI).
The agreement is part of a previously announced collaboration between Baxter and bioMérieux to improve identification and treatment of AKI.
As part of the agreement, Baxter will be bioMérieux’s exclusive distributor of the NEPHROCLEAR CCL14 test in Europe and the U.S. following regulatory approval and launch in both markets. Baxter and bioMérieux will share in-country commercialization, while bioMérieux will retain control over the regulatory approval process. – Seeking Alpha